Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -27.16%43 Current Ratio is 10.80 as of Apr. 2026, which is 19% above its 10-year median of 9.07. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 679 Healthcare Providers & Services companies, Pharma-Bio Serv ranks better than 96.32% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pharma-Bio Serv's current ratio for the quarter that ended in Apr. 2026 was 10.80.
Pharma-Bio Serv has a current ratio of 10.80. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Pharma-Bio Serv's Current Ratio or its related term are showing as below:
PBSV'
s Current Ratio Range Over the Past 10 Years
Min: 4.03 Med: 9.07 Max: 14.36
Current: 10.8
During the past 13 years, Pharma-Bio Serv's highest Current Ratio was 14.36. The lowest was 4.03. And the median was 9.07.
PBSV's Current Ratio is ranked better than 96.32% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs PBSV: 10.80
Pharma-Bio Serv (OTCPK:PBSV) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pharma-Bio Serv Current Ratio Related Terms
Pharma-Bio Serv Current Ratio Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBSV vs MGRX, BFRG, VYND: Current Ratio Comparison
For the Health Information Services subindustry, Pharma-Bio Serv's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (PBSV) has a Current Ratio of 10.80 as of Apr. 2026. This is 19% above median its historical median of 9.07. Over the past decade, Pharma-Bio Serv's Current Ratio has ranged from 4.03 to 14.36. According to the industry distribution chart, Pharma-Bio Serv ranks #25 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 3.7%.
Is Pharma-Bio Serv's Current Ratio too high?
Pharma-Bio Serv's current Current Ratio of 10.80 is 19% above median its 10-year median of 9.07. Over the past 10 years, this metric has ranged from a low of 4.03 to a high of 14.36. The Healthcare Providers & Services industry median Current Ratio is 1.47. Pharma-Bio Serv's value of 10.80 is 634.7% above this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #25 out of 679 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's Current Ratio compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #25 out of 679 companies for Current Ratio. This places Pharma-Bio Serv in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.47. Pharma-Bio Serv's value of 10.80 is 634.7% above this benchmark. Historically, Pharma-Bio Serv's own Current Ratio has ranged from 4.03 to 14.36 over the past decade. While the company's 10-year median is 9.07 vs. the industry median of 1.47, Pharma-Bio Serv has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current Current Ratio of 10.80 is 634.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current Current Ratio is 10.80, which is 19% above median its own 10-year median of 9.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current Current Ratio is 10.80, which is 19% above median its 10-year median of 9.07 and 634.7% above the Healthcare Providers & Services industry median of 1.47. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current Current Ratio is 10.80 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
Current Ratio: 10.80 (19% above median its 10-year median of 9.07)
GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
Industry Position: 634.7% above the Healthcare Providers & Services median (#25 of 679)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score
Get the complete analysis for PBSV
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
